Hepatitis B Virus-Related Acute-on-Chronic Liver Failure
Conditions
Interventions
Treatment group:artificial liver treatment
Sponsors
The Second Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Twenty patients with HBV-ACLF who underwent artificial liver treatment in the Department of Gastroenterology at our hospital were selected as the study population. The inclusion criteria were as follows: 1.Patients with underlying liver disease of chronic hepatitis B virus infection; 2.Diagnosis of HBV-ACLF meeting the COSSH ACLF diagnostic criteria, which include a history of chronic hepatitis B virus infection for at least 6 months, acute liver dysfunction, total bilirubin >=205 µmol/L, and international normalized ratio of prothrombin time >=1.5, with or without cirrhosis; 3.All patients received artificial liver treatment on the basis of comprehensive medical therapy, and the artificial liver treatment protocol involved sequential plasma exchange using a local citrate anticoagulation method combined with double plasma molecular adsorption system therapy; 4.Follow-up was conducted for a period of 90 days after the first artificial liver treatment.
Exclusion criteria
Exclusion criteria: 1. Other liver diseases not caused by HBV; 2. Liver transplantation; 3. Severe extrahepatic disease; 4. Combined with hepatocellular carcinoma and/or other organ malignancy; 5. Patients receiving glucocorticoids or immunosuppressants 6. Human immunodeficiency virus or other viral infections.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| single cell transcriptome; | — |
Secondary
| Measure | Time frame |
|---|---|
| Bulk RNA Transcriptome; | — |
Countries
China
Contacts
Public ContactQi Wei
The Second Hospital of Hebei Medical University
Outcome results
None listed